2-(4-哌啶氧基)乙酸乙酯 | 167844-03-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(4-哌啶氧基)乙酸乙酯
• 英文名称: ethyl 2-(4-piperidyloxy)-acetate
• 英文别名: ethyl 4-piperidinyloxyacetate；(piperidin-4-yloxy)-acetic acid ethyl ester；ethyl 2-(4-piperidyloxy)acetate；ethyl piperidin-4-yloxyacetate；Ethyl 4-Piperidinoxy Acetate；ethyl 2-piperidin-4-yloxyacetate
• CAS: 167844-03-3
• 化学式: C₉H₁₇NO₃
• mdl: MFCD11045904
• 分子量: 187.239
• InChiKey: VDKVPBCMAIZLLR-UHFFFAOYSA-N

物化性质

• 沸点：
  286.6±30.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-哌啶氧基)乙酸乙酯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 2-((1-((8-(4-pyridyl)-2,8-diazaspiro[4.5]dec-2-yl) carbonyl)-4-piperidyl)oxy)acetate
  参考文献：
  名称：

  Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

  摘要：

  The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00095-1
• 作为产物：
  描述：

  ethyl 2-(4-piperidyloxy)acetate hydrochloride 在 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 生成 2-(4-哌啶氧基)乙酸乙酯
  参考文献：
  名称：

  [EN] FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE
  [FR] ANTAGONISTES DU RECEPTEUR DU FIBRINOGENE ET LEUR UTILISATION

  摘要：

  公开号：

  WO2005035495A3

文献信息

• [EN] ROR NUCLEAR RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS NUCLÉAIRES ROR
  申请人：ABBVIE INC

  公开号：WO2016198908A1

  公开（公告）日：2016-12-15

  The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了式(I)化合物的药物可接受的盐、前药、生物活性代谢物、立体异构体和它们的同分异构体，其中变量如本文所述定义。本发明的化合物用于治疗免疫性疾病。
• Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
  申请人：——

  公开号：US20030055244A1

  公开（公告）日：2003-03-20

  Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis

  本发明涉及某些含有取代或未取代吡啶基的螺环化合物，其取代有碱性和酸性功能，可用于抑制血小板聚集，抑制纤维蛋白原与血小板的结合，并预防或治疗血栓形成。
• Piperidine Carboxylic Acid Derivatives of 10H-Pyrazino[2,3-b][1,4]benzothiazine as Orally-Active Adhesion Molecule Inhibitors
  作者：Toshihiko Kaneko、Richard S. J. Clark、Norihito Ohi、Fumihiro Ozaki、Tetsuya Kawahara、Atsushi Kamada、Kazuo Okano、Hiromitsu Yokohama、Masayoshi Ohkuro、Kenzo Muramoto、Osamu Takenaka、Seiichi Kobayashi

  DOI：10.1248/cpb.52.675

  日期：——

  of potent adhesion molecule inhibitors. Of these, (anti) [3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methyl-3-azabicyclo[3.3.1]non-9-yl]acetic acid 2q (ER-49890), showed the most potent oral inhibitory activities against neutrophil migration in an interleukin-1 (IL-1) induced paw inflammation model using mice, and leukocyte accumulation in a carrageenan pleurisy model in the rat, and therapeutic effect

  制备了10H-吡嗪并[2,3-b] [1,4]苯并噻嗪的新型哌啶羧酸衍生物，并评价了其对粘附分子如细胞间粘附分子-1（ICAM-1）上调的抑制活性。用含有羧酸的部分取代先前制备的衍生物的哌啶环上的甲磺酰基基团产生了许多有效的粘附分子抑制剂。其中，（反）[3-（10H-吡嗪并[2,3-b] [1,4]苯并噻嗪-8-基）甲基-3-氮杂双环[3.3.1]非-9-基]乙酸2q （ER-49890）在使用小鼠的白介素1（IL-1）诱导的爪炎症模型中显示出对中性粒细胞迁移的最强口服抑制活性，在大鼠角叉菜胶胸膜炎模型中显示了白细胞积累以及对胶原蛋白的治疗作用诱发的大鼠关节炎。
• Pyrazolones derivatives
  申请人：Nissan Chemical Industries, Ltd.

  公开号：US05968967A1

  公开（公告）日：1999-10-19

  A pyrazolone derivative represented by general formula (I) or a salt thereof: ##STR1## [wherein one of X.sup.1 and X.sup.2 is ##STR2## (wherein A is a cyano group, a cyano C.sub.1-4 alkyl group, an amino group, an amino C.sub.1-4 alkyl group, an amidino group or a guanidino group, R.sup.1 and R.sup.2 are independently hydrogen atoms, halogen atoms, C.sub.1-6 alkyl groups or the like) or the like], the other of X.sup.1 and X.sup.2 is a C.sub.1-6 alkyl group, a C.sub.3-6 alkenyl group, an aryl C.sub.1-4 alkyl group or an aryl group, one of Y.sup.1 and Y.sup.2 is ##STR3## (wherein Q is an oxygen atom or a sulfur atom, Z.sup.1 is an oxygen atom, a --NR.sup.7 -- group or a --CHR.sup.7 -- group, Z.sup.2 is a cyclic C.sub.3-7 alkylene group, a C.sub.1-3 alkylene group, a --CH.sub.2 CO-- group or --CH.sub.2 CH.sub.2 CO-- group, Z.sup.3 is an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group or the like, Z.sup.4 is a C.sub.1-3 alkylene group, and Z.sup.5 is a carboxyl group or the like, and the other of Y.sup.1 and Y.sup.2 is a D-E- group [wherein E is a bond, a C.sub.1-4 alkylene group or a phenylene group, and D is a hydrogen atom, a C.sub.1-6 alkyl group or the like which has an inhibitory action on platelet aggregation and is useful as a preventive or therapeutic agent for various thrombotic diseases.

  通用公式（I）表示的吡唑酮衍生物或其盐：其中X.sup.1和X.sup.2中的一个是（其中A是氰基，氰基C.sub.1-4烷基，氨基，氨基C.sub.1-4烷基，酰胺基或胍基，R.sup.1和R.sup.2分别是氢原子，卤素原子，C.sub.1-6烷基或类似物）之一，另一个是C.sub.1-6烷基，C.sub.3-6烯基，芳基C.sub.1-4烷基或芳基，Y.sup.1和Y.sup.2中的一个是（其中Q是氧原子或硫原子，Z.sup.1是氧原子，-NR.sup.7-基团或-CHR.sup.7-基团，Z.sup.2是环状C.sub.3-7烷基基团，C.sub.1-3烷基基团，-CH.sub.2 CO-基团或-CH.sub.2 CH.sub.2 CO-基团，Z.sup.3是氧原子，硫原子，亚砜基，磺酰基或类似物，Z.sup.4是C.sub.1-3烷基基团，Z.sup.5是羧基或类似物，Y.sup.1和Y.sup.2中的另一个是D-E-基团（其中E是键，C.sub.1-4烷基或苯基，D是氢原子，C.sub.1-6烷基或类似物，对血小板聚集具有抑制作用，并且可用作各种血栓性疾病的预防或治疗剂。
• 10-(Piperidin o-alkyl)-phenothiazines
  申请人：Roussel-UCLAF

  公开号：US04018922A1

  公开（公告）日：1977-04-19

  Novel 10-(piperidino-alkyl)-phenothiazines of the formula ##STR1## wherein X is selected from the group consisting of hydrogen, chlorine, --CF.sub.3, --OCH.sub.3 and SCH.sub.3, B and R are individually selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, Z' is selected from the group consisting of hydrogen and alkyl of 1 to 10 carbon atoms, p is 0 or 1, n is 0, 1 or 2 and A is selected from the group consisting of hydrogen, --COOR.sub.2 and --COR.sub.1, R.sub.2 is linear alkyl of 1 to 15 carbon atoms and R.sub.1 is selected from the group consisting of alkyl of 1 to 18 carbon atoms optionally containing a double bond or --O-- and a polymethoxyphenyl and their non-toxic, pharmaceutically acceptable acid addition salts having neuroleptic, analgesic, spasmolytic and antihistaminic activity and their preparation and novel intermediates.

  新颖的10-(哌啶基)-苯并噻嗪类化合物的化学式为##STR1##其中X从氢、氯、--CF.sub.3、--OCH.sub.3和SCH.sub.3组成的群体中选取，B和R分别从氢和1至4个碳原子的烷基组成的群体中选取，Z'从氢和1至10个碳原子的烷基组成的群体中选取，p为0或1，n为0、1或2，A从氢、--COOR.sub.2和--COR.sub.1组成的群体中选取，R.sub.2为1至15个碳原子的直链烷基，R.sub.1从1至18个碳原子的烷基中选取，可选含有双键或--O--和多甲氧基苯基，以及其无毒、药用可接受的酸盐，具有神经阻滞、镇痛、解痉和抗组胺活性，以及它们的制备和新颖中间体。